Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

This update of the 2013 guideline will help ensure:

- Uniform approach to molecular testing
- Improved effectiveness of treatment for patients

New Evidence-based Recommendations:

- Patients with certain biomarkers can benefit from targeted therapy
- EGFR, ALK, and ROS1 testing must be performed on all advance stage lung cancer patients

Review all of the new and updated recommendations


© 2018 CAP, IASLC, AMP. All rights reserved.

26% 25% Die of lung cancer

2nd Most common cancer in both

1:15 Develop lung cancer in a lifetime

1:17